Actinium Pharmaceuticals Inc   (ATNM)
Other Ticker:  
Price: $4.1800 $0.16 3.980%
Day's High: $4.25 Week Perf: -5.43 %
Day's Low: $ 4.02 30 Day Perf: -24.96 %
Volume (M): 139 52 Wk High: $ 14.70
Volume (M$): $ 580 52 Wk Avg: $8.17
Open: $4.02 52 Wk Low: $4.00

 Market Capitalization (Millions $) 113
 Shares Outstanding (Millions) 27
 Employees 23
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -50
 Cash Flow (TTM) (Millions $) -29
 Capital Exp. (TTM) (Millions $) 0

Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for the treatment of cancer. The company's primary focus is on developing alpha particle immunotherapy, a form of targeted radiation therapy that selectively targets cancer cells while minimizing damage to healthy tissue.

Actinium has developed a proprietary technology called Actinium-225/Bismuth-213 Generator (ABG) which is used to produce isotopes that can be used in targeted alpha particle therapy. The company is working on developing multiple drug candidates based on this technology, which can target a range of cancers including acute myeloid leukemia, multiple myeloma, and non-Hodgkin's lymphoma.

One of the most promising drug candidates is Iomab-B, which is designed to target patients with relapsed/refractory acute myeloid leukemia (AML). The drug works by targeting the CD45 antigen found on the surface of leukemic cells and delivering a lethal dose of radiation. Iomab-B has shown promising results in clinical trials, with a 100% complete remission rate in patients who received a transplant following treatment.

Actinium is also involved in the development of a series of other drug candidates, including Actimab-A, Actimab-M, and Actimab-MDS. These drugs are designed to target other forms of cancer, including multiple myeloma and myelodysplastic syndrome.

The company has established collaborations with a number of other organizations, including Memorial Sloan-Kettering Cancer Center, Fred Hutchinson Cancer Research Center, and the National Cancer Institute. These collaborations allow Actinium to access the expertise of world-renowned scientists and clinicians, as well as access to patient populations for clinical trials.

Actinium has a strong management team with extensive experience in the biopharmaceutical industry. The company is led by Sandesh Seth, who joined Actinium as CEO in 201 Prior to joining Actinium, Seth worked in various executive positions at Vela Pharmaceuticals, Celgene Corporation, and Sun Pharmaceuticals. The company has also attracted a team of experienced scientists and researchers, with expertise in nuclear medicine, radiochemistry, and drug development.

In summary, Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for the treatment of cancer. The company is at the forefront of developing alpha particle immunotherapy, a form of targeted radiation therapy, and has a number of promising drug candidates in development, including Iomab-B, Actimab-A, Actimab-M, and Actimab-MDS. The company has established collaborations with world-renowned institutions and has a strong management team and a team of experienced scientists and researchers.

   Company Address: 275 Madison Avenue, 7th Fl New York 10016 NY
   Company Phone Number: 677-3870   Stock Exchange / Ticker: NYSE ATNM
   ATNM is expected to report next financial results on March 30, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Lipocine Inc

the Major Pharmaceutical Preparations company in the fiscal time-frame ending September 30 2023

In its most recent fiscal period Lipocine Inc increased a shortfall per share at $-1.27 per share, opposite of $-0.03 per share a year before reporting season, In the prior reporting season LPCN realized $-0.68 per share.

Bioxytran Inc

Bioxytran Inc Faces Investor Concerns as Operating Deficit Grows in Q3 2023

Following the recent announcement of operating deficit for the third quarter of 2023, Bioxytran Inc, a major player in the pharmaceutical preparations industry, has captured investors' attention. The company's financial performance has raised questions about its ability to generate revenue in the near future.
For the third quarter of 2023, Bioxytran Inc reported an operating deficit of $-0.985464 million. This represents a worsening of the deficit compared to the same period in 2022, where it stood at $0.014225 million. However, the main concern for investors lies in the absence of any reported revenue during this time frame.

Briacell Therapeutics Corp

Briacell Therapeutics Corp Releases Fourth Quarter Fiscal Results - Showcasing Impressive Growth in Major Pharmaceutical Preparations Sector

The May to July 31, 2023 reporting season has resumed, and many companies, including those in the Major Pharmaceutical Preparations sector, have announced their financial numbers. Among these companies is Briacell Therapeutics Corp, which recently published an operating loss of $-7.705761 million for the financial fourth quarter of 2023. Additionally, Briacell Therapeutics Corp has reported a net deficit of $-14.300 million for the interval between May and July 31, 2023, which is a significant decline compared to the balanced books it maintained during the same period last year.
One noteworthy aspect is that the value of accounts receivable for Briacell Therapeutics Corp is still below the previous year's level; however, there has been some sequential progress. It is also important to mention that the company has observed a shortfall of $-20.30 million and has generated zero revenue during the financial period of 2023.

Gt Biopharma Inc

GTBP Reports Impressive Operating Surplus of $3.122 Million in Third Quarter Earnings Season

The stock market has always been a dynamic and exciting place, filled with ups and downs that keep investors on their toes. Today, we turn our attention to the Major Pharmaceutical Preparations industry and delve into the third quarter of 2023 numbers. Specifically, we examine Gt Biopharma Inc's financial report from July to September 30, 2023, which showcased an operating surplus of $3.122 million.
It's important to note that Gt Biopharma Inc has not cited any revenue yet, making the operating surplus even more impressive. As industry reporters analyze these figures, the prevailing situation of the organization becomes clearer. To truly understand the significance of the third quarter of 2023 earnings season, let's compare it with the same period in 2022.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc Overcomes Revenue Setback, Prepares for Resurgence in Q4 2023

Enanta Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections, recently announced its financial results for the July to September 30, 2023, period. During this period, the company reported an increase in losses, which expanded from $1.27 per share a year prior to $1.32 per share. However, it is worth noting that the earnings per share (EPS) improved from -$1.86 in the preceding reporting period.
The revenue for the same period decreased by 6.817% to $18.93 million compared to $20.32 million in the previous reporting period. While sequentially, the revenue advanced slightly by 0.212% from $18.89 million. This decline in revenue could raise concerns, as it may indicate slowing demand for Enanta Pharmaceuticals Inc's products.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com